About sacituzumab govitecan
Antibody-drug conjugate; Trop-2-directed chemotherapy
Used for
- Certain unresectable or metastatic triple-negative breast cancers after prior systemic treatments.
- Certain hormone-receptor-positive, HER2-negative advanced breast cancers after prior endocrine therapy and systemic treatments.
Usual adult dose
10 mg/kg intravenously on days 1 and 8 of each 21-day cycle, until progression or unacceptable toxicity; maximum 10 mg/kg per dose.
Common side effects
- Low white blood cell counts, including neutropenia
- Diarrhea, nausea, vomiting, or abdominal pain
- Hair loss and fatigue
- Anemia or reduced appetite
Important warnings
- Can cause severe, life-threatening neutropenia and serious diarrhea.
- Severe allergic or infusion reactions can occur; monitored infusion is required.
- May cause fetal harm; pregnancy testing and effective contraception are recommended.
- UGT1A1 poor metabolizers may have greater risk of severe or fatal neutropenia.
Pregnancy
May harm an unborn baby. Avoid during treatment and for six months after the last dose; effective contraception is recommended.
Breastfeeding
Do not breastfeed during treatment or for one month after the last dose.
Interactions
- UGT1A1 inhibitors may increase exposure to the active SN-38 component.
- UGT1A1 inducers may reduce SN-38 exposure and effectiveness.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.